Biotech and Pharma

Metsera falls sharply after Pfizer agrees to buy the weight-loss drug start-up in a deal that could be worth more than $10 billion.

The biotech reported positive trial data for a treatment targeting patients with gastrointestinal stromal tumors.

The bullish note comes after the company reached a landmark deal with the U.S. government.

The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven treatments.

Tesla declines after the electric-vehicle maker's shareholders approve a massive pay package for CEO Elon Musk.

China’s commitment to innovation poses a long-term threat to U.S. companies. What it needs now is for its citizens to spend more.

Nex-z is the most closely watched drug in Intellia’s development pipeline. The company said in September that it planned to submit the drug for regulatory approval in 2028.

Duolingo declines sharply after its bookings forecast misses estimates, and DoorDash tumbles following an earnings miss.

Contingent value rights have become common in biotechnology deals. More than half of all transactions this year include them, according to a Jefferies report in October.

The agreement, announced by the White House, potentially unlocks a major new market for the mega-blockbuster drugs.

The vaccine company reports better-than-expected quarterly results.

Shares in AMD rise after the chip maker posts better-than-expected third-quarter earnings and revenue.

iRhythm Technologies stock has doubled this year.

The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.

AMD beats expectations, Mamdani wins NYC mayoral election, Bitcoin briefly dips below $100,000, and more news to start your day.

The biotechnology company reported a smaller-than-expected loss in its quarterly figures.

Shares in data analytics software developer Palantir tumble even as the company tops analysts' earnings estimates.

The Danish company’s latest offer is more than 30% about what Pfizer initially agreed to pay, not counting potential milestone payments.

Third-quarter revenue falls, driven by declining demand for Pfizer’s Covid-19 products.

The company believes the Food and Drug Administration may deal a setback to one of its investigational therapies.

Pfizer has now filed a suit in federal court, following its claim in state court on Friday. It is riding Trump-era political currents in its efforts to save the deal.

iPhone maker Apple and cloud-computing and online retailing giant Amazon post better-than-expected earnings.

“The market is entirely too complacent about downside risks,” says one observer. The troubles go beyond a few rough earnings reports.

Revenue attributed to AbbVie’s oncology and aesthetics portfolio declined in the quarter.

Apple is betting on a big holiday season, Netflix weighs Warner Bros. bid, Pfizer and Novo Nordisk find themselves in a bidding war, and more news to start your day.